Add BrightSurf on Google Email

AFM-Telethon, Nobel Laureate Drew Weissman and neuromuscular disease expert James Dowling join forces to develop the next generation of gene therapies

A new two-year research program aims to develop novel delivery systems for gene therapies, specifically targeting muscle fibres and muscle stem cells using lipid nanoparticles. The project will focus on advancing innovative therapies for neuromuscular disorders, including Duchenne muscular dystrophy and dysferlinopathy.

“Average” human genome described for first time, with implications for disease risk

The study analyzed data from nearly 1 million individuals, revealing that everyone has around five million genetic variants, including 10,000 that alter gene sequences and 50 rare variants of uncertain clinical relevance. Most people would be categorized as at high risk of genetic risk for around three conditions, highlighting the impo...

SourceUniversity of Exeter·JournalGenome Medicine·TypeObservational study·DateOct 22, 2026

Scientists identify Id3 as a molecular brake that could enhance ultrasound-induced bone regeneration

Scientists have identified Id3 as a key molecular regulator of low-intensity pulsed ultrasound (LIPUS)-induced bone formation. An Id3 inhibitory peptide, rID3, combined with LIPUS, enhances osteogenesis and improves bone-defect healing in mice. The study provides a potential strategy for enhancing ultrasound-based bone regeneration.

SourceEditorial Office of West China School of Stomatology, Sichuan University·JournalInternational Journal of Oral Science·TypeExperimental study·DateOct 15, 2026

Chinese Medical Journal review highlights new directions in pulmonary arterial hypertension

A new review highlights how molecular biology advances are reframing PAH as a complex vascular remodeling disease driven by endothelial dysfunction, chronic inflammation, metabolic dysregulation, and genetic susceptibility. Emerging therapies target the BMP/TGF-β pathway, growth factor signaling, and inflammatory pathways.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateAug 11, 2026

Thirty years later: A reappraisal of Alzheimer’s disease risk in Japanese APOE-e4 homozygotes

Researchers at Niigata University conducted the first comprehensive reappraisal of Alzheimer's disease risk in Japanese APOE-e4 homozygotes, finding a substantially lower risk than previously cited estimates. The study suggests that the risk is comparable to estimates reported in large studies of people with European ancestry.

SourceNiigata University·JournalMolecular Neurodegeneration·DateJun 29, 2026

Predicting genetic risk for Type 1 diabetes just got more accurate thanks to UC San Diego study

The study demonstrates that the T1GRS tool can identify children and adults at high risk for Type 1 diabetes earlier than current methods, enabling preventive measures before the disease develops. The researchers grouped individuals into four sub-types based on genetic features, each with unique clinical profiles and outcomes.

SourceUniversity of California - San Diego·JournalNature Genetics·TypeComputational simulation/modeling·DateApr 30, 2026

New gene therapy delivery device could let hospitals create personalized nanomedicines on-demand

A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.

SourceFrontiers·JournalFrontiers in Science·TypeSystematic review·DateJun 26, 2025

New study reveals how 5'LysTTT tRNA fragments protect neurons during botulinum toxin exposure

Scientists have uncovered a previously unknown mechanism explaining how neurons survive botulinum neurotoxin type A exposure. The research found that specific tRNA fragments interact with key proteins and RNA molecules involved in regulating ferroptosis, supporting neuronal survival by blocking cell death pathways.

SourceGenomic Press·JournalGenomic Psychiatry·TypeExperimental study·DateMay 20, 2025

Substance use accelerates brain aging through distinct molecular pathways, groundbreaking study reveals

Researchers identified unique biological mechanisms that cause premature aging in the brains of individuals with alcohol, opioid, and stimulant use disorders. Different substances appear to hijack the brain's natural aging rhythm through distinct molecular mechanisms, though some pathways are shared across different substance types.

SourceGenomic Press·JournalGenomic Psychiatry·TypeExperimental study·DateApr 29, 2025

New study reveals potential link between GLP1 agonists and depression: Calls for urgent attention

A recent study published in Current Neuropharmacology suggests a potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists and depression, particularly in individuals with low dopamine function. The authors urge caution and recommend genetic testing to identify individuals at risk before prescribing these medications.

SourceBentham Science Publishers·JournalCurrent Neuropharmacology·DateApr 17, 2025

Largest ever genome-wide association study uncovers new drug targets and potential therapies for osteoarthritis

A recent study has made a breakthrough in understanding the genetic underpinnings of osteoarthritis by identifying 962 genetic markers associated with the condition. The researchers found 513 new genetic markers that were not previously reported, providing potential new drug targets and opportunities for repurposing existing medications.

SourceUniversity of Maryland School of Medicine·JournalNature·TypeMeta-analysis·DateApr 15, 2025

Genetic predisposition to sedentary behavior increases the risk of cardiovascular diseases

A new study found that genetic predisposition to sedentary behavior is associated with a higher risk of developing the most common cardiovascular diseases. Individuals with the highest genetic predisposition accumulated more daily sedentary time and had a 20% higher risk of cardiovascular diseases.

SourceUniversity of Jyväskylä - Jyväskylän yliopisto·JournalBritish Journal of Sports Medicine·DateApr 8, 2025

New study helps optimize gene therapy

A multidisciplinary team has generated an atlas to optimize gene therapy delivery, providing researchers with insights into the most effective viral vectors for specific tissues. The study identifies AAV4 as a promising vector for vascular and pancreatic applications, offering new possibilities for treating conditions like diabetes.

SourceBaylor College of Medicine·JournalMolecular Therapy·TypeExperimental study·DateApr 1, 2025

Breakthrough study sheds new light on causes of spina bifida and potential treatments

A new study published in Nature reveals critical insights into how spina bifida develops, identifying specific steps in embryogenesis that contribute to the condition. The research also suggests a potential link between new DNA mutations and disease risk, opening the door for future treatments such as gene therapy and targeted drugs.

SourceRady Children's Institute for Genomic Medicine·JournalNature·TypeExperimental study·DateApr 1, 2025

Study finds knowledge of genetics and genomic medicine crucial for mental health providers to deliver informed, personalized care

A new study emphasizes the importance of understanding genetic underpinnings of psychiatric disorders for mental health providers. Key findings highlight the application of genetic information in risk assessment, diagnosis, treatment selection, and patient education, while also considering ethical considerations.

SourceRady Children's Institute for Genomic Medicine·JournalAmerican Journal of Psychiatry·TypeSystematic review·DateMar 26, 2025

Activating complex regions of the genome to treat rare diseases

Scientists at Duke University have discovered a master epigenetic switch that can be activated using CRISPR to compensate for missing genes in Prader-Willi syndrome. This approach could potentially treat the disease by turning on naturally suppressed genes from one parent, addressing the underlying genetic defect.

SourceDuke University·JournalCell Genomics·TypeExperimental study·DateFeb 12, 2025